trastuzumab
Showing 1 - 25 of 525
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,
Not yet recruiting
- Her 2 Positive Breast Cancer
- +2 more
- Sacituzumab Govitecan
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 25, 2023
GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)
Recruiting
- GastroEsophageal Cancer
- Gastric Cancer
- Neratinib
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 25, 2023
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in Scottsdale,
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +5 more
- Trastuzumab
- +2 more
-
Scottsdale, Arizona
- +2 more
Jan 31, 2023
Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)
Completed
- Advanced Gastric Carcinoma
- Trastuzumab
- +2 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Aug 15, 2023
t Pathologic Complete Response Observed in HER2 Positive Breast
Completed
- HER2+ Breast Cancer
- Trastuzumab
-
Rawalpindi, Punjab, PakistanRawalpindi Medical University
Jun 26, 2023
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +4 more
- Necitumumab
- +4 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,
Completed
- HER2 Positive Breast Carcinoma
- +6 more
- Utomilumab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 22, 2022
Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)
Not yet recruiting
- Breast Cancer
- Trastuzumab deruxtecan
- +9 more
-
Malmö, Sweden
- +6 more
Jun 8, 2023
HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)
Completed
- HER2-positive Breast Cancer
- HS022
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023
Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)
Not yet recruiting
- Breast Cancer
- Pyrotinib
- +7 more
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Dec 2, 2022
Breast Cancer, Tumor Metastasis Trial in Houston (Trastuzumab, RAD001)
Completed
- Breast Cancer
- Neoplasm Metastasis
- Trastuzumab
- RAD001
-
Houston, TexasUT MD Anderson Cancer Center
Sep 30, 2022
Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,
Terminated
- Breast Neoplasms
- Malignant Tumor of the Breast
- Trastuzumab
- +2 more
-
Multiple Locations, Texas19 Sites
Nov 29, 2022
Metastatic HER2-Positive Breast Cancer Trial in United States (Gemcitabine, Trastuzumab, Pertuzumab)
Active, not recruiting
- Metastatic HER2-Positive Breast Cancer
- Gemcitabine
- +2 more
-
Hartford, Connecticut
- +4 more
Dec 1, 2022
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease Trial in Tampa, Evanston (Radiation Therapy,
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Radiation Therapy
- +2 more
-
Tampa, Florida
- +1 more
Dec 30, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copanlisib
- +2 more
-
Los Angeles, California
- +4 more
Jul 19, 2022
Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Dalpiciclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 10, 2022
HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)
Recruiting
- HER2-positive Breast Cancer
- Dendritic Cell (DC1) Vaccine
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Dec 28, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Esophagogastric Adenocarcinoma Trial (Pembrolizumab, Trastuzumab, FLOT)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Pembrolizumab
- +2 more
- (no location specified)
Aug 17, 2022
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,
Recruiting
- Brain Metastases
- +2 more
- Trastuzumab
- +3 more
-
Saint Louis, Missouri
- +1 more
Nov 8, 2022
HER2-positive Breast Cancer Trial (Paclitaxel + Trastuzumab, Trastuzumab)
Not yet recruiting
- HER2-positive Breast Cancer
- Paclitaxel + Trastuzumab
- Trastuzumab
- (no location specified)
May 24, 2022
Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation Trial in United States (Pembrolizumab, Trastuzumab)
Not yet recruiting
- Esophageal Cancer
- +2 more
- Pembrolizumab
- Trastuzumab
-
Baltimore, Maryland
- +8 more
Nov 3, 2023
Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)
Recruiting
- Breast Cancer
- Durvalumab
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Aug 5, 2022